Salt

Researchers are evaluating the safety, how the body processes the drug, how the drug affects the body, and the effectiveness of RO7268489 as an added treatment to ocrelizumab in adults with progressive multiple sclerosis (PMS). This phase II study focuses on people aged 18 to 60 with PMS who meet specific criteria, aiming to understand the impact of adding RO7268489 to their existing ocrelizumab therapy. After the main double-blind phase, an open-label extension may allow some participants to receive RO7268489 openly. Participants will receive either RO7268489, ocrelizumab, or a placebo according to a set schedule during the trial. RO7268489 and ocrelizumab are given as drugs, with the placebo group serving as a comparison. Following the double-blind period, eligible participants can join an open-label phase to receive RO7268489. Treatment plans and schedules are carefully followed as outlined in the study arms. Throughout the study, researchers will monitor participants for the time until the first confirmed worsening of disability lasting at least 12 weeks, over approximately 110 weeks. Participants will undergo regular assessments to track disease progression and safety. The study includes careful screening and ongoing evaluations to ensure participant health and to measure the effects of the treatments over time.

Researchers are conducting a Phase 3 study to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of ABP 692 with Ocrelizumab (both US and EU versions) in people with relapsing-remitting multiple sclerosis (RRMS). The study aims to show similarity between these treatments by measuring how the drugs behave in the body and their effects on suppressing new active brain lesions over 24 weeks using MRI scans. Participants will receive intravenous infusions of either ABP 692, Ocrelizumab (US), or Ocrelizumab (EU). The study design allows comparison between these three groups to assess how the drugs are processed and how well they control disease activity. Infusions are given according to the study schedules, and the effects are monitored over the following weeks. During the study, participants will have regular assessments including brain MRI scans to count new lesions, blood tests to measure drug levels, and neurological evaluations to track disease status. The main outcomes include drug concentration over time and the number of new brain lesions up to week 24. Safety and clinical effects will also be observed throughout the study period, which includes screening and follow-up visits.